Corbus Cystic Fibrosis Data May Justify Longer, Larger Study
Executive Summary
Safety was the primary endpoint in a Phase II study for the inflammation-targeting drug anabasum, but Corbus believes an efficacy signal viewed outside of the secondary endpoints justifies further development.
You may also be interested in...
Corbus Takes On New Cystic Fibrosis Endpoint With Lenabasum
The US FDA has agreed to Corbus' plan to use pulmonary exacerbations as the only primary endpoint in a new large Phase II study, which is powered to serve as a registrational study.
ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III
The ACR/ARHP Annual Meeting in San Diego offered new details from studies of new and existing therapies across a range of rheumatic diseases, from rheumatoid arthritis to rare diseases. Scrip shares notes here from interviews with Lilly, Ironwood, Corbus and Samumed.
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.